Previous Close | 5.14 |
Open | 5.19 |
Bid | 4.00 x 1300 |
Ask | 5.50 x 1200 |
Day's Range | 4.99 - 5.44 |
52 Week Range | 3.96 - 34.61 |
Volume | |
Avg. Volume | 417,796 |
Market Cap | 308.451M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.10 |
Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.25 |
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines Cash balance of $337.0M expected to fund operations into 2024 CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and first quarter 2022 financial results. “We are making s